Despite the immense therapeutic promise of small interfering RNA (siRNA), the single most significant restraint limiting the widespread adoption and expansion of the segment is the technical challenge of safe and effective drug delivery. Naked, unmodified siRNA molecules face several physiological hurdles: they are highly susceptible to rapid enzymatic degradation by nucleases in the...